CONTENTS

PITFALLS IN THE USE OF BRAIN SLICES 1
K. H. REID,* H. L. EDMONDS JR.,† A. SCHURR,† M. T. TSENG‡ and C. A. WEST,† Laboratory for Cellular Neuroscience, Departments of Anesthesiology,† Surgery, Physiology* and Anatomy,‡ School of Medicine, University of Louisville, Louisville KY 40292, U.S.A.

THE AUDITORY EVOKED POTENTIAL IN THE RAT — A REVIEW 19
N. A. SHAW, Department of Physiology, School of Medicine, University of Auckland, Auckland I, New Zealand

CHARACTERISTICS OF THE SYMPATHETIC PREGANGLIONIC NEURON AND ITS SYNAPTIC INPUT 47
W. LASKEY and C. POLOSA, Department of Physiology, McGill University, Montreal, Quebec, Canada

PURINERGIC MECHANISMS IN EPILEPSY 85
M. DRAGUNOW, Department of Anatomy, Faculty of Medicine, Auckland University, Auckland, New Zealand

INTERACTIONS BETWEEN CHOLINERGIC AND PEPTIDERGIC SYSTEMS IN THE CEREBRAL CORTEX AND HIPPOCAMPUS 109
Y. LAMOUR* and J. EPELBAUM,† *INSERM U 161, 2 rue d'Alesia, 75014 Paris, France and †INSERM U 159, 2 ter rue d'Alesia, 75014, Paris, France

BRAIN DEVELOPMENT IN DWARF MICE 149
T. NOGUCHI, Department of Physiology, Toho University School of Medicine, Ohmori-nishi, Tokyo-143, Japan

INFLUENCE OF ETHANOL ON NEURONAL AND SYNAPTIC MATURATION IN THE CENTRAL NERVOUS SYSTEM — MORPHOLOGICAL INVESTIGATIONS 171
D. G. JONES, Department of Anatomy and Neuroscience Centre, University of Otago, PO Box 913, Dunedin, New Zealand

DEVELOPMENT OF VENTRAL SPINAL MOTONEURONE FIBRES: A CORRELATIVE STUDY OF THE GROWTH AND MATURATION OF CENTRAL AND PERIPHERAL SEGMENTS OF LARGE AND SMALL FIBRE CLASSES 199
J. P. FRAHER, G. F. KAAR, D. C. BRISTOL and J. P. ROSSITER, Department of Anatomy, University College, Cork, Ireland

THE PHOSPHORYLATION OF MYELIN PROTEINS 241
J. B. ULMER, Department of Cell Biology, Yale University School of Medicine, New Haven, CT 06510, USA

NEURAL SUBSTRATES OF AGGRESSION AND FLIGHT IN THE CAT 261
A. SIEGEL and C. B. POTT, Department of Neuroscience, New Jersey Medical School, Newark, New Jersey 07103, USA

COMPLEX-CELL RECEPTIVE FIELD MODELS 285
H. SPITZER* and S. HOCHSTEIN,† *Department of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 3200, Israel and †Department of Neurobiology, Institute of Life Sciences, Hebrew University, Jerusalem, Israel

CHOLINESTERASE AND ITS MOLECULAR FORMS IN PATHOLOGICAL STATES 311
Z. RAKONCZAY, Central Research Laboratory, Albert Szent-Györgyi Medical University, Szeged, Hungary

CELL DEATH AND THE ELIMINATION OF RETINAL AXONS DURING DEVELOPMENT 331
J. M. PROVIS and P. L. PENFOLD, Save Sight and Eye Health Institute, Department of Clinical Ophthalmology, University of Sydney, Australia

ELECTROPHYSIOLOGY OF BENZODIAZEPINE RECEPTOR LIGANDS: MULTIPLE MECHANISMS AND SITES OF ACTION 349
P. POLC, Hasenrainstrasse 31, 4102 Binningen, Switzerland

FUNCTIONAL *IN VIVO* CORRELATES OF THE BENZODIAZEPINE AGONIST–INVERSE AGONIST CONTINUUM 425
C. R. GARDNER, Roussel Laboratories, Kingfisher Drive, Covingham, Swindon, Wiltshire, U.K.

CELL–PATTERNING DURING SEXUAL NEUROGENESIS 477
G. BERNROIDER, Institute of Zoology, University of Salzburg, Hellbrunner Str. 34, A–5020 Salzburg, Austria

ELECTRICALLY COUPLED BUT CHEMICALLY ISOLATED SYNAPSES: DENDRITIC SPINES AND CALCIUM IN A RULE FOR SYNAPTIC MODIFICATION 507
J. WICKENS, Department of Anatomy and the Neuroscience Centre, University of Otago, PO Box 913, Dunedin, New Zealand

INDEX

Acetazolamide 99
Acetylcholine
  colocalisation with VIP 123
  in dementia 131
  interaction with thyrotropin releasing hormone 112
  metabolism by SPN axon terminals 70
  modulation of aggression 274
  relation with cholecystokinin 125
  relation with somatostatin 119, 120
  release in brain, effect of adenosine 97
  release in brain, effect of enkephalins 126
  release by SPN axon terminals 69, 70
Acetylcholine — peptide colocalisation 128, 133
Acetylcholine receptors, SPNs 56, 72
Acetylcholinesterase in pathological states
  brain tumours 318
  dementias 312
  Down's syndrome 315
  experimental allergic neuritis 320
  Hirschsprung's disease 320
  Huntington's disease 316
  mania, depression and schizophrenia 317
  neural tube defects 318
  Parkinson's disease 315
  motor neuron degenerative diseases 323
  muscular diseases 321
  paroxysmal nocturnal hemoglobinuria 324
A–current, SPNs 52
Adenosine
  anticonvulsant action 86, 96
  benzodiazepine ligands and uptake of 381
  endogenous anticonvulsant effects 88, 92
  role in etiology of epilepsy and nerve cell death 99
  source in brain 97
Adenosine analogues, clinical usefulness in epilepsy 98
Adenosine metabolites, anticonvulsive effects 95
Adenosine–3',5'–monophosphate, in brain during seizures 96
Adenosine–3',5'–monophosphate-dependent kinase, myelin basic protein 245
S–Adenosylhomocysteine, anticonvulsant effects 96
Adrenal gland, GABA–benzodiazepine interaction 370
Adrenaline, sedative effects 277
Adrenergic blocking agents, effect on auditory evoked potentials 34
α-Adrenergic receptors, SPNs 57, 72
Affective attack, dopaminergic mechanisms 277
Affective defense behaviour
  afferent connections 265
  cholinergic mechanisms 273
  efferent connections 266
  motor mechanisms 272
  noradrenergic mechanisms 277
  opiate mechanisms 278
  sensory mechanisms 272
  serotonergic mechanisms 276
Age, auditory evoked potentials 27
Aggression, neural substrates 261–283
  affective defense behaviour 265, 272, 273, 276, 278
  cholinergic mechanisms 273
  dopaminergic mechanisms 276
  flight behaviour 268, 272, 275
  noradrenergic mechanisms 277
  opiate mechanisms 278
  quiet biting attack behaviour 262, 270, 274, 275
AHR 11797 460
Alcoholics, neuronal changes 188
Allopurinol 99
Alpidem, *in vivo* activity 458
Alzheimer's disease
  cholinesterase in 312
  peptides and acetylcholine in 131
γ–Aminobutyric acid
  coexistence with somatostatin 119
  effect on SPNs 58
γ–Aminobutyric acid–benzodiazepine linkage 351
  behaviour 376, 422
  benzodiazepine receptor ligand effects 369, 437
  benodiazepine receptors, three state model 352
  biochemistry and morphology 374
  electrophysiology 370, 421
  endogenous ligands 392
  evoked potentials 351
  extracellular studies *in vivo* and *in vitro* 356
  intracellular studies 364
  mechanism of benzodiazepine action 370
  model 355
  partial agonists and multiplicity 391
  patch-clamp studies 368
  retina 370
  Xenopus oocytes 370
Aminophylline, convulsant effects 89
Amniotic fluid, cholinesterase in pathological states 318
Amyotropic lateral sclerosis, cholinesterase in 323
Anaesthetics, effect on auditory evoked potentials 34
Androgenisation, neonatal
  central effects 492
  peripheral effects 491
Anencephaly, cholinesterase in 318
Anterior pituitary gland, dwarf mice 158
Anxiety — benzodiazepines 350
  effect of β-carbolines 436
  effect of CGS compounds 455
  GABA involvement 376
  effects of PK 8165 and PK 9084 443
  purinergic involvement 384
  effect of Rol5–1788 431
  effect of RU 31719, RU 32698 and RU 32514 446
  effect of RU 43028 444
Aortic chemoreceptors 64
Apoptosis 337
Arginine-vasopressin, role in brain sexual differentiation 487
Arterial baroreceptors, SPN activity 63
Arterial chemoreceptors 64

Artificial cerebrospinal fluid 6
Astrocytes
  effect of ethanol on development 177
  motoneurone development 202
Audiogenic seizures, effect of adenosine 86
Auditory evoked potential, rat 19-45
  age 27
  animal models of otoneurological disease 38
  drugs 30
  gender 30
  seizure activity 36
  sleep 37
  temperature 36
  waveform morphology and origins 20
Autonomic neurons, effect of benzodiazepine ligands 369
Autoreceptors 128
Axon calibre-myelin sheath thickness relationships 227
Axon guidance, spinal motoneurons 201
Axon sprouting, effect of ethanol 178
Axons, retinal
  aetiology of excess 333
  branching 336
  cell death 337
  competitive interactions 341
  electrical activity 343
  numbers during development 331
  role of afferents 342
  trophic substances and growth factors 342
Axons, ventral motoneurons
  differentiation 220
  myelin sheath growth 217
  node development 209
  segregation 209

Baroreceptors, SPN activity 63
Behaviour, dwarf mice 166
Benzodiazepine agonist–inverse agonist continuum, *in vivo* correlates 425–476
  β–carbolines 435
  CGS 8216, CGS 9895, CGS 9896 and S–135 455
  CL 218,872 and analogues 452
  cyclopyrrolones 449
  diazepines 430
  PK 8165 and PK 9084 442
  RU 31719, RU 32698 and RU 32514 446
  RU 43028 and analogous quinoline derivatives 444
  zolpidem and alpidem 458
Benzodiazepine receptors
  endogenous ligands 428
  factors affecting *in vivo* activity 426
  heterogeneity 427
  inverse agonism 430
  methylxanthine effects 90
Benzodiazepine receptor ligands 349–423
  behavioural effects 376, 422
  biochemistry and morphology of BZR 352
  electrophysiology 370, 396–402, 421
  endogenous ligands 392
  GABAergic inhibition 351–380, 391, 421
  model of receptors 352
  neuronal membrane properties 387
  neuropeptide interaction 387
  partial agonists and multiplicity 390
  purinergic modulation of central neuronal activity 381
Benzodiazepines, anticonvulsant effects 99
Blood-brain barrier, adenosine analogues 88
Brain cell counting, sexual neurogenesis 479
Brain development in dwarf mice 149–170
Brain growth, effect of ethanol 172
Brain slices, pitfalls in use 1–18
  bathing medium 5
  chambers 5
  environment 5
  flow and diffusion 9
  interpretation of drug effects 12
  metabolic integrity 2
  preparation 1
  responses to stress 10
  sampling variability 11
  structural integrity 2
  temperature 8
Brainstem auditory evoked potentials 20
  animal models of neurological disease 38
  development 27
  drugs 30
  gender 30
  malnutrition 28
  myelination 29
  old age 29
  sleep 37
  temperature 36
Brainstem compression, auditory evoked potential 38
Brainstem, GABA–benzodiazepine interaction 359
Brain tumours, cholinesterase in 317
Brattleboro rat, sexual neurogenesis 487, 497
t–Butyl–bicyclophosphorothionate 352
N–Butyl–β–carboline–3–carboxylate 394
Butyrylcholinesterase in pathological states
  brain tumours 318
  dementias 313
  neural tube defects 318
  schizophrenia 317

Caffeine, convulsant effects 89
Calcium
  in bathing medium for brain slices 6
  influx and long-term potentiation 509
  regulation of neuronal influx 509, 513
  role in epilepsy 97
  spine neck resistance 515
Calcium channels
  receptor-operated 511, 517
  subtypes 510
  synaptic enhancement 508, 509
  voltage-sensitive 508, 510, 518
Calcium conductance, benzodiazepine receptor ligands 288
Calcium-dependent kinases, myelin basic protein 245
Calcium entry blockers, effect on brain slices 12
Calmodulin, in dendritic spines 512
Carbamazepine, anticonvulsant effects 98
β–Carbolines 354
  in vivo activities 435
β–Carboline-like benzodiazepine receptor ligands 393
Carotid glomus, chemoreceptors 64

Cat
complex cell receptive fields 300
neural substrates of aggression and flight 261–283
Catecholamine receptors, SPNs 56
Cell cultures, myelin basic protein phosphorylation 249
Cell death during development, visual system 333, 337
apoptosis 337
neuron survival factors 341
Cell density, sexual neurogenesis 479
Cell-patterning during sexual neurogenesis 477–506
brain sexual dimorphisms 478
methods of coordinate-dependent brain cell counting 479
sex–specific hypothalamic cell patterns 484
Cerebellar auditory evoked potentials 26
Cerebello-pontine angle tumours 38
Cerebellum
effect of ethanol on growth 172
effect of ethanol on mature dendrites 186
effect of ethanol on neuronal development 174, 181
GABA–benzodiazepine interaction 361
Cerebral cortex
effect of ethanol on mature dendrites 190
effect of ethanol on neuronal development 176
Cerebrospinal fluid
artificial 6
cholinesterase in dementias 313
Cervical transitional zone 206
CGS 8216, *in vivo* activity 455, 457
CGS 9895, *in vivo* activity 455
CGS 9895, *in vivo* activity 455
Chemoreceptors, arterial 64
Chlordiazepoxide 365, 366
2–Chloroadenosine, anticonvulsant effects 86
p–Chlorophenylalanine, modulation of aggressive behaviour 275
Chlorpromazine, effect on auditory evoked potentials 34
Cholecystokinin
anatomical localisation 124
benzodiazepine interaction 387
electrophysiological effects 125
pathology 125
receptors 124
release 125
Cholinergic activity, dwarf mice 154
Cholinergic drugs, effect on auditory evoked potentials 34
Cholinergic mechanisms of aggression 273
Cholinergic neurons, peptidergic control 129
Cholinergic–peptidergic systems in cortex and hippocampus 109–148
cholecystokinin 124
colocalisation 133
dementia 131
enkephalins 126
functional implications 128
luteinizing hormone releasing hormone 121
peptidergic control of cholinergic neurons 129
somatostatin 118
substance P 114
thyrotropin releasing hormone 111
vasoactive intestinal peptide 122
Cholinesterase, molecular forms in pathological states 311–330
dementias 312
Down's syndrome 315
Guillan–Barré syndrome and experimental allergic neuritis 320
Hirschsprung's disease 320
human primary brain tumours 317
Huntington's disease 316
mania, depression and schizophrenia 317
motoneurone degenerative diseases 323
muscle diseases 321
neural tube defects 318
Parkinson's disease 315
paroxysmal nocturnal hemoglobinuria 324
trembler disease 323
Cl^-, in bathing medium for brain slices 7
Cl^- channel binding, benzodiazepine receptors 352
CL 218,872 and analogues, *in vivo* activities 452
CNS–PNS transitional zone 205
Complex cell receptive fields 285–309
cell type classification 294
classification 286
contrast reversal grating stimulation 289
linearity tests 289
models 291, 303
neuronal filters 287
parallel or hierarchical processing? 297
response-form dependence on stimulus parameters 300
sinusoidal grating stimulation 288, 294
spatial frequency tuning 295
Contrast reversal grating stimulation 289
Convulsions
effect of β–carbolines 435
effect of CL 218,872 452
effect of Rol5–1788 432
Cortical auditory evoked potential 23
development 27
drugs 31
malnutrition 28
Corticospinal neurons, effect of ethanol 176
Cuneate nucleus, GABA–benzodiazepine interaction 351, 358
2',3'–Cyclic nucleotide 3'–phosphohydrolase in brain of dwarf mice 150, 157
phosphorylation of myelin proteins 251
Cyclohexyladenosine, anticonvulsant effects 86
Cyclopyrrolones, *in vivo* activities 449

Decremental segment 230
Dejerine–Sottas disease, cholinesterase in 323
Delayed anovulatory syndrome 491
Dementias
cholinesterase in 312
peptides and acetylcholine in 131
Dendritic spines
chemical compartments 512
neck resistance and $(Ca^{2+})_i$ 515
neck resistance in LTP 518
simulation 520
synaptic efficacy 514
Dendritic tree, effects of ethanol 181, 186
Deoxyribonucleic acid, in brain of dwarf mice during development 152, 157
Depression, cholinesterase in 317

Development
auditory evoked potential 27
cell death and elimination of retinal axons 331–347
effect of ethanol on neuronal populations 174
inherited hypothyroid mouse 159
Little mouse 156, 166
Snell pituitary dwarf mouse 149, 166
spinal motoneurons 201
Diazepam
effect on adenosine actions on neurons 381
GABA involvement in effects of 351–380
effect on spinal cord 356
Diazepam binding inhibitor 392
Diazepines, *in vivo* activities 430
Diencephalon, SPN activity 67
Dihydropyridines
effect on brain slices 12
voltage-sensitive calcium channels 510
6,7–Dimethoxy–4–ethyl–β–carboline–3–carboxylate, *in vivo* activity 435
Distal central internode, myelin sheath growth 219
Dopamine, in brain of dwarf mice 154
Dopaminergic mechanisms of aggression 276
Dorsal raphé nucleus, GABA–benzodiazepine interaction 359
Down's syndrome, cholinesterase in 315
Drifting sinusoidal grating stimulation 289
Duchenne muscular dystrophy, cholinesterase in 321
Dwarf mice, brain development 149–170
Dynorphin, effect on acetylcholine release 127

Electrically coupled synapses 507–528
Electroconvulsive shock, effect on auditory evoked potentials 36
Embryonic spinal cord, GABA–benzodiazepine interaction 366
EMD 28422 386
EMD 41717 460
Enflurane, effect on auditory evoked potentials 34
Enkephalins
anatomical localisation 126
biological effects 126
electrophysiological effects 127
receptors 126
release and degradation 126
Enkephalin receptors, SPN axon terminals 73
Epilepsy, benzodiazepine receptors 354, 360
Epilepsy, purinergic mechanisms 85–108
adenosine as an endogenous anticonvulsant substance 92
anticonvulsant effects of adenosine 86, 96
anticonvulsant effects of adenosine metabolites 95
clinical relevance 98
Epilepsy, effect of Ro15–1788
Ethanol, effect on auditory evoked potentials 35
Ethanol, CNS maturation 171–197
brain growth 172
dendritic tree 181
development of neuronal populations 174
mature dendrites 186
myelination 173
neural topography 178
synaptic maturity 182
withdrawal 188
Ethyl–β–carboline–3–carboxylate 354
in vivo activity 435, 442
N–Ethylcarboxamido–adenosine, anticonvulsant effects 86, 92
Excitant amino acid receptors, SPNs 54
Experimental allergic neuritis, cholinesterases in 320
Experimental autoimmune myasthenia gravis 324

α–Fetoprotein 479
FG 7142, *in vivo* activity 435
Flight behaviour
cholinergic mechanisms 275
efferent connections 269
physiology 272
Flumazenil 355, 356, 382
Flunarizine, effect on brain slices 13
Flunitrazepam, visualisation of benzodiazepine binding sites 354
Foetal alcohol syndrome 172, 175
Fourier sinusoidal grating stimulation 288

Gabor functions 287
Gangliosides, in brain of dwarf mice 153
Gender, auditory evoked potentials 30
Gilles de la Tourette's syndrome 324
Gliomas, cholinesterase in 317
Glucose, in bathing fluid for brain slices 7
Glutamate
release in brain, effect of adenosine 97
effect on SPNs 54
Glycine, effect on SPNs 58
Glypiation 249
Granule cells, effect of ethanol 174, 181, 186
G–ratio 229, 230
Growth, brain development in dwarf mice 149–170
Growth factors, neuron survival 342
Growth hormone, effect on brain of dwarf mice 150, 153, 156
Guanosine–3',5'–monophosphate, in brain, effect of benzodiazepine receptor agonists 437
Guillain–Barré syndrome, cholinesterases in 320
Gunn rat, auditory evoked potentials 39

Habenulo–interpeduncular pathway, substance P in 114
Halothane, effect on auditory evoked potentials 34
Harmane 393
Hepatic encephalopathy 324
Hippocampus
effect of ethanol on mature dendrites 188
effect of ethanol on neuronal development 176
GABA–benzodiazepine interaction 362, 364, 374
synaptic enhancement 509
Hirschsprung's disease, cholinesterase in 320
Hormone-deficient growth disturbances 149–170
Hubel and Wiesel's classification of complex cells 286
3–Hydroxy-methyl-β-carboline, *in vivo* activity 438

5–Hydroxytryptamine
in brain of dwarf mice 154
role in aggressive behaviour 275
role in auditory activity 35
5–Hydroxytryptamine receptors, SPNs 54, 73
Hypothalamus
affective defense behaviour 265, 272
flight behaviour 268
GABA–benzodiazepine interaction 361
quiet biting attack behaviour 262, 270
sex–specific cell patterns 484
Hypothermia
effect on auditory evoked potentials 36
effect on seizures 87
Hypothyroidism, auditory evoked potentials 39
Hypoxanthine, anticonvulsive effects 95

Ileum, GABA–benzodiazepine interaction 369
Inferior colliculus, GABA–benzodiazepine interaction 360
Inherited hypothyroid mouse, brain development 157
Inhibitory amino acid receptors, SPNs 58
Inosine
anticonvulsive effects 95
neuromodulatory role at benzodiazepine receptors 383, 392
Ischaemia, effect on brain slices 10

Kanamycin, effect on auditory evoked potentials 39
Kernicterus, auditory evoked potentials 39
Ketamine, effect on auditory evoked potentials 33
Kindled seizures, effect of adenosine and its analogues 86

Learning, synaptic enhancement 507, 508
Leptazol, induced seizures, effect of Rol5–1788 432
Limb nerves, development 201
Little mouse
behavioural abnormalities 166
brain development 156
Locus coeruleus, GABA–benzodiazepine interaction 359
Long latency auditory evoked potential 26
development 27
Long-term potentiation 507
calcium influx 509
hypotheses 516
spine neck resistance 518
synaptic modification 508
voltage–sensitive calcium channels 518
Lumbar transitional zone 206
Luteinizing hormone, neonatal androgenization 495
Luteinizing hormone releasing hormone
anatomical localisation 121
electrophysiology 121

Magnesium, in bathing medium for brain slices 7
Malnutrition, effect on auditory evoked potentials 28
Mania, cholinesterase in 317
Masculinization 491, 495
Medial preoptic area 477, 482, 484, 487, 496
Meningiomas, cholinesterase in 317
Meprobamate 99
3–((Methoxycarbonyl)amino)–β–carboline, *in vivo* activity 438
N–Methyl–D–aspartate 507
calcium channels 511, 515, 517
Methylxanthines, convulsant effects 89
Microencephaly, ethanol–induced 172
Midazolam 357, 364
Middle latency auditory evoked potential 25
development 27
Monkey, complex cell receptive fields 301
Mossy fibre topography, effect of ethanol 178
Motoneurone cell death 202
Motoneurone fibres, ventral spinal, development 199–239
axon segregation and transitional node development 209
central–peripheral transitional zone 205
differentiation of large and small axons 220
early development 201
functional correlates 229
myelin sheath growth 217
myelin sheath thickness–axon calibre relationships 227
Motor endplate disease, cholinesterases in 323
Motor neuron degenerative diseases, cholinesterases in 323
Muscarinic receptors, SPNs 56, 72
Muscle
adenosine induced relaxation 87
β–carbolines and relaxation 437
cyclopyrrolones and relaxation 451
Muscular dysgenesis, cholinesterases in 323
Muscular dystrophies, cholinesterase in 321
Myelin
composition and function 242
phosphoprotein phosphatases in 248
protein kinases in 245
Myelin-associated glycoprotein 252
Myelination
in brain of dwarf mice 150, 157
effect of ethanol 173
role in auditory evoked potentials 28
ventral motoneurone axons 209
Myelin basic protein 242
phosphoprotein phosphatases 248
phosphorylation *in vitro* 247, 248, 252
phosphorylation *in vivo* 245, 250
phosphorylation model 253
protein kinases acting on 245
regulation of phosphorylation 254
related polypeptides 251
Myelinolysis, auditory evoked potentials 40
Myelin sheath growth
distal central internode 219
peripheral–central comparisons 220
proximal peripheral internode 218
ventral root internodes 217
Myelin sheath, myelin basic protein phosphorylation 254
Myelin sheath thickness–axon calibre relationships 227
Myopathies, cholinesterase in 321

Naloxone, effect on aggressive behaviour 279

Neocortex, GABA–benzodiazepine interaction 362
Nepenthin 395
Nerve cell death 333, 337
  role of adenosine 100
Nerve conduction 230
Nerve Growth Factor 342
Neural topography, effect of ethanol 178
Neural tube defects, cholinesterase in amniotic fluid 318
Neuritic plaques, Alzheimer's disease 312
Neurofibrillary tangles, Alzheimer's disease 312
Neuromuscular development 230
Neuronal elimination during development 337
Neuronal membranes, effect of benzodiazepine receptor ligands 387
Neuronal migration, effect of ethanol 177
Neurons, effect of ethanol on development
  cerebellum 174, 186
  cerebral cortex 176, 190
  dendritic tree 181
  hippocampus 176, 188
  morphology 177
  synaptic maturity 182
Neuron survival
  competition hypothesis 341
  electrical activity 343
  role of afferents 342
  tropic substances and growth factors 342
Neuropeptide–benzodiazepine interaction 387
Neuropeptide Y 119
Neurotransmitters, release by SPN axon terminals 69
Nicotinamide, effect on anticonvulsant action of adenosine 86
Nitrendipine, binding sites and synaptic zones 511
Nociception, benzodiazepine involvement 358
Nodal development 209
Nodes of Ranvier 209
  location 210
  maturation 215
Noradrenaline, effect on SPNs 57
Noradrenergic mechanisms of aggression 277
Nucleus interfascicularis hypoglossi, SPN activity 67
Nucleus paragigantocellularis, SPN activity 66

Olfactory bulb, effect of ethanol on development 186
Olfactory cortex, GABA–benzodiazepine interaction 365
Oligodendrocytes
  development 205
  myelin basic protein phosphorylation 249, 252
Opiate mechanisms of aggression 278
Opiate receptors 126
Optic axons
  aetiology of excess 333
  cell death 337
  number during development 331
Otoneurological disease, animal models 38
Ototoxicosis, auditory evoked potentials 39
Oxytocin receptors, SPNs 56

Pain, aggression 272
Palingenesis 249
Parkinson's disease, cholinesterase in 315
Parotid gland, effects of substance P 116
Paroxysmal nocturnal hemoglobinuria, cholinesterase in 324
Partial agonists, benzodiazepine receptors 391
Patch-clamp, GABA–benzodiazepine interaction in neurons in tissue culture 368
Pentobarbital, effect on auditory evoked potentials 30
Peptidergic–cholinergic systems 109–148
  cholecystokinin 124
  colocalisation 133
  dementia 131
  enkephalin 126
  functional implications 128
  luteinizing hormone releasing hormone 121
  peptidergic control of cholinergic neurons 129
  somatostatin 118
  substance P 114
  thyrotropin releasing hormone 111
  vasoactive intestinal peptide 122
Permanent anovulatory sterility 491
Phentolamine, effect on auditory evoked potentials 34
L–Phenylisopropyladenosine, anticonvulsant effects 86, 88
Phenytoin 99
Phosphoprotein phosphatases, myelin basic protein 248
Pick's disease, cholinesterase in 315
Pineal body, dwarf mice 166
Pituitary cells, effect of TRH 113
Pituitary gland, dwarf mice 158
PK 8165 and 9084, *in vivo* activities 442
P_0 phosphorylation 252
Polyphosphoinositides, covalent attachment to myelin basic protein 249
Potassium, brain slice bathing medium 6
Potassium conductance
  benzodiazepine receptor ligands 387
  effect of substance P 118
Predatory attack behaviour 262, 270
Premazepam, *in vivo* activity 434
Progressive muscular atrophy, cholinesterase in 323
Propranolol, effect on auditory evoked potentials 34
Propylthiouracil, effect on auditory evoked potentials 39
Protein, synthesis in brain slices 2
Protein kinases, myelin basic protein 245
Proximal peripheral internode, myelin sheath growth 218
Purinergic mechanisms in epilepsy 85–108
Purinergic modulation of neuronal activity, benzodiazepine interaction 381
Purkinje cells, effect of ethanol 174, 186

Quiet biting attack behaviour
  afferent connections 262
  cholinergic mechanisms 274
  dopaminergic mechanisms 276
  efferent connections 264
  motor mechanisms 271
  sensory mechanisms 270
  serotonergic mechanisms 275

Raphe nuclei, SPN activity 67
Receptive field models, complex cells 291
Receptor-operated channels 511
Receptor profile, SPNs 53
REM sleep/seizure arrest 93
Renshaw cells, effect of substance P 117
Respiration, modulation of SPN firing 59
Retina, GABA–benzodiazepine interaction 370
Retinal axons
  aetiology of excess axons 333
  cell death 337
  competitive interactions 341
  electrical activity 343
  neuronal elimination 337
  neuron survival 341
  numbers during development 331
  role of afferents 342
  trophic substances and growth factors 342
Retinal ganglion cells
  axonal branching 336
  cell death 337
  numbers during development 331
Rhythmic modulation of tonic activity, SPNs 59
Ro15–1788 355
  in vivo activity 430
Ro15–3505, *in vivo* activity 433
Ro15–4513 394
Ro16–6028, *in vivo* activity 434
Ro17–1812, *in vivo* activity 434
Rostral ventrolateral medulla, SPN activity 66
RU 31719, *in vivo* activity 446
RU 32514, *in vivo* activity 446
RU 32698, *in vivo* activity 446
RU 39419, *in vivo* activity 445
RU 40410, *in vivo* activity 444
RU 42382, *in vivo* activity 445
RU 43028, *in vivo* activity 444

S–135, *in vivo* activity 458
Schizophrenia, cholinesterase in 317
Schwann cells
  axon guidance 202
  development 205
  node maturation 215
  transitional 205, 209
Sedation, benzodiazepine–GABA interaction 377
Seizures
  effect of adenosine 86
  effect on auditory evoked potentials 36
  effect of β–carbolines 435
  effect of Ro15–1788 432
Senescence, auditory evoked potentials 29
Senile dementia, cholinesterase in 312
Sensory input, SPN activity 61
Septum
  peptidergic control of cholinergic neurons 129
  effects of TRH 113
Serotonergic drugs, effect on auditory evoked potentials 35
Serotonergic mechanisms of aggression 275
Sexually dimorphic nucleus 477, 479, 487, 496, 501
Sexual neurogenesis, cell patterning 477–506
  brain sexual dimorphisms 478
  methods of coordinate–dependent brain cell counting 479
  neonatal androgenization 491
  sex–specific hypothalamic cell patterns 484
Sinusoidal grating stimulation 287
  cell type classification 294
Sleep
  effect on auditory evoked potentials 37
  benzodiazepine–GABA interaction 377
Snell pituitary dwarf mouse
  behavioural abnormalities 166
  brain development 149
Sodium, in bathing medium for brain slices 6
Sodium conductance, benzodiazepine receptor ligands 389
Soma–dendritic membrane, synaptic contacts 49
Somatic afferents, SPN activity 61
Somatomedin C, in brain of dwarf mouse 154
Somatostatin
  anatomical localisation 118
  biochemical effects 119
  in brain in dementia 132
  in brain of dwarf mouse 154
  coexistence with other transmitters 118
  electrophysiological effects 119
  receptors 119
  relations with acetylcholine 120
  release 119
  in SPNs 69
Somato–sympathetic reflex 61
Spatial frequency tuning of cortical neurons 295
Spina bifida, cholinesterase in amniotic fluid 318
Spinal cord
  benzodiazepine–GABA interaction 351, 356, 366
  benzodiazepine–purinergic interaction 385
  effect of substance P 116
  substance P in 114
Spinal motoneurons 199–239
  axon segregation and transitional node development 209
  central–peripheral transitional zone 205
  differentiation of large and small axons 220
  early development 201
  functional correlates 229
  myelin sheath growth 217
  myelin sheath thickness–axon calibre relationships 227
  effects of TRH 113
Spine apparatus, calcium in 512
SR 95195, *in vivo* activity 455
Stress, effect on brain slices 10
Stress protein, brain slices 2
Substance P
  anatomical localisation 114
  electrophysiology 116
  receptors and release 115
  in SPNs 67, 69
Substance P receptors, SPNs 55
Substantia nigra
  benzodiazepine–GABA interaction 360
  benzodiazepine–purinergic interaction 385
Suprachiasmatic nucleus, dwarf mouse 166
Supraspinal neurons, projection to SPN nuclei 65
Suproclone, *in vivo* activity 452
Suriclone, *in vivo* activity 451
Sympathetic preganglionic neurons 47–84
  anatomy 48
  electrophysiological properties 50
  membrane receptor profile 53
  release of neurotransmitter by axon terminals 69

sources of synaptic activity 60
tonic activity 58
Synapses, electrically coupled
hypotheses 516
regulation of calcium influx 509
simulation 520
spine location 513
Synaptic current, spine parameters 514
Synaptic enhancement 509, 516
Synaptic maturity, effect of ethanol 182
Synaptosomes, effect of ethanol 182

Temperature
effect on auditory evoked potentials 36
effect on brain slices 8
Testosterone, neonatal androgenization 492
1,2,3,4–Tetrahydro–9–aminoacridine, treatment of dementia 315
Theophylline, convulsant effects 89
Thyroidectomy cells, anterior pituitary of dwarf mice 158
Thyrotropin–releasing hormone
anatomical localisation 111
electrophysiological effects 112
interactions with acetylcholine metabolism and cholinergic drugs 112
receptors 111
effects in septum, interaction with cholinergic neurons 113
Thyroxin, effect on brain of dwarf mice 150, 153, 157
Tissue culture
neurons, patch–clamp studies 368
spinal cord cells 366
Tonic synaptic activity, SPNs 58
Tranquillizers
benzodiazepine agonist–inverse agonist continuum 425
benzodiazepine–GABA interaction 377
Transitional node development 209
Transitional zone 205
cervical 206
functional correlates 229
lumbar 206
Trembler mice, cholinesterase in 323
Tribulin 394
Troponin–I 253

Vasoactive intestinal polypeptide
anatomical localisation 122
biological effects 123
colocalisation with acetylcholine 123
electrophysiological effects 123
receptors 123
Vasopressin receptors, SPNs 56
Ventral root internodes, myelin sheath growth 217
Ventral spinal motoneurone fibres, development 199–239
axon segregation and transitional node development 209
central–peripheral transitional zone 205
differentiation of large and small axons 220
early development 201
functional correlates 229
myelin sheath growth 217
myelin sheath thickness–axon calibre relationships 227
Ventrolateral pontine reticular formation, SPN activity 67
Vestibular nuclei, GABA–benzodiazepine interaction 359
Viscero–sympathetic reflex 63
Visual complex cell receptive field models 285–309
Visual system, cell death and axon elimination during development 331–347
Voltage–sensitive calcium channels 508, 510, 515, 518

White rami, relation with SPN 49
Withdrawal, ethanol 188

Xanthine derivatives
adenosine antagonists 91
convulsant effects 89
Xenopus oocytes, GABA–benzodiazepine complex 370

ZK 91296, *in vivo* activity 441
ZK 93423, *in vivo* activity 440
ZK 93426, *in vivo* activity 440
ZK 95926, *in vivo* activity 442
Zolpidem 357, 376, 378
in vivo activity 458
Zopiclone, *in vivo* activity 449